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ABSTRACT 
Amyloid-β peptides and hyper-phosphorylated tau are the main pathological hallmarks of Alzheimer’s disease 
(AD). Given the recent failure of several large-scale clinical trials and the lack of disease-modifying pharmaco-
logical treatments, there is an urgent need to develop alternative therapies. A clinical grade human CTX0E03 
neural stem cell line has recently passed phase I trials in people with stroke. However, this cell line has not been 
investigated in other neurodegenerative disorders. This study investigates the survival of CTX0E03 cells under 
conditions based on the underlying AD pathology. Cell viability assays showed a concentration dependence of 
this cell line to the toxic effects of Aβ1-42, but not Aβ1-40, and okadaic acid, a phosphatase 2A inhibitor. Notably, 
CTX0E03 cell line displayed toxicity at concentrations significantly higher than both rat neural stem cells and 
those previously reported for primary cultures. These results suggest CTX0E03 cells could be developed for 
clinical trials in AD patients.  
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INTRODUCTION  
 
Dementia affects over 35 million people 
worldwide, and this is set to rise to 115 mil-
lion by 2050 (Broadstock et al., 2014). This 
devastating condition incurs enormous per-
sonal cost to those affected, with an estimat-
ed worldwide financial cost of $ 604 billion 
(Wimo et al., 2013). Alzheimer’s disease 
(AD) is the most common cause of dementia, 
affecting up to two-thirds of people with the 
condition (Cornutiu, 2015). The progressive 
nature of the cognitive decline in people with 
AD leads to the need for complex treatment 
and care. Thus, AD represents a major and 
increasing public health concern and there is 
an urgent imperative to develop more effec-
tive therapies both to treat and to delay the 
onset of disease.  
Major pathological hallmarks of AD are 
the deposition of aggregated amyloid β-
protein (Aβ) contributing to the formation of 
extracellular amyloid plaques (senile pla-
ques) and the intra-neuronal accumulation of 
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hyper-phosphorylated tau protein, which, 
over time, lead to synaptic dysfunction, neu-
ronal loss and neuroinflammation (Hardy 
and Selkoe, 2002; Reitz and Mayeux, 2014). 
Cleavage of amyloid precursor protein 
(APP) by β- and γ-secretase to generate sol-
uble Aβ species that form additional Aβ 
plaques can induce neurotoxicity and synap-
tic failure (Haass and Selkoe, 2007). Aβ1-40 
and Aβ1-42 are two prevalent forms that show 
a high tendency to initiate congregation into 
soluble forms and eventually to form insolu-
ble aggregated fibrils as amyloid plaques 
(Lui and Zhao 2004).  
In the UK, there are four licensed phar-
macological treatments only for AD, viz., 
donepezil, galantamine and rivastigmine, 
acetylcholinesterase inhibitors, which are 
prescribed for mild to moderate AD; and the 
NMDA receptor antagonist memantine that 
is licensed for moderate to severe AD (Rafii 
and Aisen, 2015). Whilst these treatments 
provide symptomatic benefit and are cost-
effective, their benefits extend for an average 
of only 6-24 months, and none targets the 
underlying AD pathology and disease pro-
cesses (Bond et al., 2012). Although these 
treatments are enormously valuable in treat-
ing symptoms, there is an urgent need to de-
velop better, more effective treatments de-
signed to ameliorate the disease progression 
(Broadstock et al., 2014). 
The recent failures of several large-scale 
phase III trials aimed at reducing the amy-
loid burden in AD have emphasized the ne-
cessity to broaden treatment approaches 
(Doody et al., 2013, 2014; Salloway et al., 
2014). One potential treatment that has gen-
erated considerable excitement is stem cell 
implantation. Some successes have been re-
ported with cellular therapies in a number of 
other neurodegenerative diseases, such as 
Parkinson’s disease, and a number of trans-
genic animal studies point to this as a poten-
tially exciting therapeutic option in the 
treatment of AD (Chen and Blurton-Jones, 
2012; Blurton-Jones et al., 2014; Oh et al., 
2014; Buttery and Barker, 2014). There are, 
however, a number of challenges to over-
come before studies in AD patients can be 
considered. Firstly, viable candidate human 
grade cell have to be available and capable 
of surviving in the toxic AD brain environ-
ment, as Aβ species have a reproducible tox-
ic impact on cultured cortical neurons and 
correlations have been reported between the 
severity of Aβ plaques and reduction in en-
dogenous neurogenesis (Chuang, 2010; Mu 
and Gage, 2011). Secondly, the abnormally 
hyper-phosphorylated tau protein in AD 
brain aggregates into neurofibrillary tangles 
in neurons correlating with the blockage of 
intracellular trafficking of neurotrophins and 
other functional proteins (Wang et al., 2014). 
However, the roles of tau phosphorylation in 
neurogenesis still are not clear, with studies 
reporting beneficial effects of tau hyper-
phosphorylation on an adult stem cell neuro-
genesis, but others showing tau phosphoryla-
tion not participating in the proliferation of 
neural precursors (Schindowski et al., 2008; 
Hong et al., 2011).  
A human grade neural stem cell line, 
CTX0E03, has recently been developed (Pol-
lock et al., 2006). This cell line is a clonal 
human cortical multipotent stem cell line 
created by genetic modification of first tri-
mester human fetal cortical cells with a sin-
gle-copy integration of c-mycERTAM fusion 
gene. Assays for cell line identity (molecular 
assays using qRT-PCR, telomerase assay, 
southern blotting, karyotyping and cellular 
phenotype using immunocytochemistry) 
have been developed and a number of safety 
aspects of the c-mycER technology have 
been confirmed in vitro to rule out the possi-
bility of reactivation of cells by re-exposure 
to 4-OHT, tamoxifen or endogenous steroid 
hormones (Pollock and Sinden, 2008). In 
addition, the cell line has shown to confer 
benefit in rodent studies of stroke (Mack, 
2011; Smith et al., 2012; Hassani et al., 
2012; Hicks et al., 2013). A phase Ia clinical 
trial in people with stroke has shown good 
tolerability with encouraging indications of 
benefit (PISCES trial, NCT01151124), and a 
phase II study is about to commence.  
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In order to assess whether the CTX cell 
line affords long term benefit to AD patients, 
the key question is the tolerance of these 
cells to Aβ and hyper-phosphorylated tau. 
Thus this study investigated the resistance of 
CTX0E03 cells to the toxicity of oligomeric 
amyloid-β species and to okadaic acid, a 
phosphatase inhibitor. 
 
MATERIALS AND METHODS 
CTX0E03 cell culture 
CTX0E03 cells were obtained from Re-
Neuron (UK). Derivation, culturing, and 
characterization of the cells were as previ-
ously described (Pollock et al., 2006). 
CTX0E03 cells were routinely cultured at 
37 °C under humidified atmosphere of 5 % 
CO2 on mouse laminin-I (20 μg/ml, Path-
Clear) freshly coated flask in Dulbecco’s 
modified Eagle’s medium nutrient F-12 
HAM mixture (Sigma) containing 10 ng/ml 
basic fibroblast growth factor (PeproTech), 
20 ng/ml epidermal growth factor (Pepro-
Tech), 100 nM 4-OHT (Sigma), 200 μM L-
ascorbic acid (Sigma), 2 mM Glutamax sup-
plement (Gibco), and 1X N-2 supplement 
(Gibco). At 70-90 % confluence, cells were 
passaged using Accutase solution (Sigma) 
for 2-5 min at 37 °C and sedimented at 
1000 g for 5 min. Cells were reseeded for 
expansion in supplemented media for exper-
imental use. All experiments were conducted 
using CTX0E03 cells between passages 33 
to 36. 
 
Neural stem cell culture 
Rat fetal neural stem cells (NSCs) (Invi-
trogen), isolated from cortices of fetal (em-
bryonic day 14) Spraque-Dawley rats, were 
expanded on 0.01 % poly-L-ornithine solu-
tion (Sigma)-coated flask in KnockOutTM 
DMEM/F12 medium supplemented with 
20 ng/ml EGF, 20 ng/ml bFGF, StemPro® 
NSC SFM supplement, and 2 mM Glutamax 
(all from Invitrogen). Cells were passaged 
and reseeded as described above when cells 
reached 80-90 % confluency. Rat fetal NSCs 
used in the study were passaged not more 
than 3 times. 
Amyloid preparation  
Oligomeric Aβ1-40 and Aβ1-42 peptides 
(California Peptide Research) were prepared 
as previously described (Dahlgren et al., 
2002). In briefly, peptides were dissolved in 
hexafluoro-2-propanol (Sigma), divided into 
smaller aliquots, dried and the peptide films 
stored at -80 °C. Soluble peptides were pre-
pared by diluting peptide films in anhydrous 
dimethylsulfoxide (DMSO) (Sigma) to 
5 mM, then further diluted to 100 μM in 
phosphate-buffered saline (PBS), and incu-
bated at 4 °C for 24 h before adding to cells.  
 
Okadaic acid preparation 
Okadaic acid (OA) (Abcam) was dis-
solved in DMSO, diluted to desired concen-
trations, and stored at 4 °C until used. 
 
Cell treatment 
CTX0E03 cells or rat fetal NSCs were 
seeded onto precoated 96-well plates at 
50,000 cells/ml. Cells were treated with Aβ1-
40 and Aβ1-42 at 0.5, 1, 5, 10, and 15 μM, or 
with OA at 0.5, 1, 5, 10, and 15 nM. Vehicle 
control cultures were treated with PBS or 
DMSO (for Aβ and OA respectively). Cells 
were incubated at 37 °C for 24 h prior to cell 
viability assay. 
 
Cell viability assay 
Cells were incubated with PrestoBlue 
(Invitrogen) for 30 min at 37 °C, and cell 
viability then was measured in a FlexStation 
3 microplate reader at an excitation of 
535 nm and emission of 615 nm.  
 
Lactate dehydrogenase (LDH)-cytotoxicity 
assay 
LDH-cytotoxicity assay was conducted 
according to the manufacturer’s protocol 
(Abcam) (Lai et al., 2014). In short, culture 
medium of treated cells was transferred into 
a 96-well plate containing substrate mixture 
and after 30 min incubation at room tem-
perature, LDH activity was measured at 
A450 nm in a FlexStation 3 microplate reader, 
with reference wavelength of 650 nm. 
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Statistical analysis 
All assays were conducted in three indi-
vidual experiments in triplicate and reported 
as mean ± SD. Statistical analysis was evalu-
ated using One-way analysis of variance 
(ANOVA), followed by Bonferroni Post-
Hoc analysis using Graph-Pad Prism soft-
ware (Graph Pad Software version 5.0a, 
USA). Statistical significance is accepted 
when p < 0.05. 
 
RESULTS 
Effects of oligomeric amyloid β-peptides on 
CTX0E03 cells 
In order to investigate whether clinical 
grade CTX0E03 cells were affected by oli-
gomeric Aβ1-40 and Aβ1-42 (Figure 1A), cell 
viability assays were performed, which do 
not show any significant effect of Aβ1-40 
relative to vehicle control (Figure 1B), but 
there is significantly decrease in cell viability 
with Aβ1-42 over the range of 5 to 15 μM re-
sulting to 80.9 %, 79.8 % and 75.4 % rela-
tive to control (50 % effective concentration 
(EC50) = 36.43 μM) (Figure 1C). 
Cytoxicity by Aβ1-42 was due to 
membrane damage as demonstrated by LDH 
release modestly by up to 12.0 % from 
treated CTX0E03 cells with 15 μM of Aβ1-42 
(Figure 2B) and, as expected, this was not 
observed with of Aβ1-40 treatment (Figure 
2A). 
 
Effects of OA on CTX0E03 cells 
OA is a protein phosphatase inhibitor 
used to induce tau hyper-phosphorylation. 
Treatment of CTX0E03 cells with OA re-
sulted in loss of cell viability (EC50 = 
1.66 nM) (Figure 3A) and release of LDH by 
reaching to 8.6 %, 11.6 %, 21.6 %, 53.2 %, 
and 58.2 % over the range of 0.5-15 nM of 
OA exposure (Figure 3B), but at a 1,000-fold 
lower concentration than that required using 
Aβ1-42. 
Figure 1: Effects of oligomeric Aβ peptides on CTX0E03 cell viability. Primary structure of Aβ peptides 
used (A). Cells were incubated for 24 h in the presence of indicated concentrations of oligomeric Aβ1-
40 (B) and Aβ1-42 (C). Cell viability was measured using PrestoBlue reagent. Controls contained vehi-
cle. Results are reported as mean ± SD of three individual experiments performed in triplicate. Statisti-
cal analysis was evaluated using ANOVA followed by Bonferroni Post-Hoc analysis. ***p < 0.001 
compared to control 
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Figure 2: Effects of oligomeric Aβ peptides on CTX0E03 cell permeability. Cells were incubated for 24 
h in the presence of indicated concentrations of oligomeric Aβ1-40 (A) and Aβ1-42 (B) prior to performing 
LDH assay. Results are reported as mean ± SD of three individual experiments performed in triplicate. 
Statistical analysis was evaluated using ANOVA followed by Bonferroni Post-Hoc analysis. **p < 0.01, 
***p < 0.001 compared to control 
Figure 3: Effects of okadaic acid on CTX0E03 cell viability and permeability. Cells were incubated for 
24 h in the presence of indicated concentrations of okadaic acid and cell viability (A) and permeability 
(B) was measured using PrestoBlue reagent and LDH assay respectively. Results are reported as 
mean ± SD of three individual experiments performed in triplicate. Statistical analysis was evaluated 
using ANOVA followed by Bonferroni Post-Hoc analysis. ***p < 0.001 compared with control 
 
 
 
Effects of oligomeric amyloid β-peptides 
and OA on neural stem cells 
The susceptibilities of CTX0E03 cells to 
Aβ peptides and OA were compared with 
those of rat fetal NSCs., the latter being more 
sensitive were more sensitive, viz., viability 
in presence of Aβ1-42 and OA had EC50 of 
11.89 μM and 1.20 nM respectively and 
LDH release in a concentration-dependent 
manner compared with control (Figure 4). 
Again, Aβ1-40 was inactive over the concen-
tration range tested. 
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Figure 4: Effects of oligomeric Aβ peptides and okadaic acid on NSC viability and permeability. Cells 
were incubated for 24 h in the presence of indicated concentrations of oligomeric Aβ peptides or oka-
daic acid and cell viability (A, B, E) and permeability (C, D, F) was measured using PrestoBlue rea-
gent and LDH assay respectively. Results are reported as mean ± SD of three individual experiments 
performed in triplicate. Statistical analysis was evaluated using ANOVA followed by Bonferroni Post-
Hoc analysis. **p < 0.01, ***p < 0.001 compared to control 
 
 
 
DISCUSSION 
We demonstrate that Aβ1-42, but not Aβ1-
40, at μM range were toxic to clinical grade 
CTX0E03 stem cells over a 24-h exposure. 
Rat fetal NSCs were more sensitive. Both 
cell lines were 1,000-fold more sensitive to 
OA toxicity under the same experimental 
settings. 
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In vitro neurotoxicity studies have re-
ported that oligomeric Aβ species are sub-
stantially more toxic (EC50 ≤ 10 μM) to neu-
ronal cortical cultures than either protofibrils 
or fibrils (EC50 > 10 μM) (Ahmed et al., 
2010; Kitiyanant et al., 2012; Dai et al., 
2013). The underlying mechanism of Aβ oli-
gomer toxicity to cortical neurons includes 
induction of Ca2+ entry through NMDA and 
AMPA receptors, causing mitochondrial 
Ca2+ overload, subsequent oxidative stress 
and mitochondrial membrane depolarization 
(Butterfield et al., 2007, Alberdi et al., 
2010). Western blotting has revealed a se-
quential up-regulation of Bim (within 24 h) 
and down-regulation of Bcl-2 (after 48 h) 
leading to activation of pro-apoptotic factors 
including Bax and subsequent neuronal cell 
death (Kudo et al., 2012). Moreover, 10 μM 
Aβ1-42 treatment of rat cortical cultures 24 h 
also causes nearly 50 % apoptotic cell death, 
manifested by increases in apoptotic protein 
expression, including increased activated 
caspase-3 and elevation in level of reactive 
oxygen species (Thangnipon et al., 2012, 
2013; Suwanna et al., 2014). Aβ is also toxic 
to various cell lines, e.g., PC12 cell line 
(Feng et al., 2013). In addition, there is an 
association between the amount of Aβ oli-
gomers in cerebrospinal fluid and cognitive 
decline (Santos et al., 2012), and specific 
forms of oligomers are associated with syn-
aptic and cognitive dysfunction (Lesne et al., 
2006; Ono et al., 2009).  
CTX0E03 cell line is relatively tolerant 
to the in vitro effects of different species of 
oligomeric Aβ. However, Aβ levels in post-
mortem AD brain are in pM to nM range 
(Eucher et al., 2007). That Aβ1-40 was non-
toxic (≤ 15 µm for 24 h) to CTX0E03 cells 
and rat fetal NSCs are in agreement with a 
previous study showing that Aβ1-40 does not 
interfere with cell survival of mouse neural 
stem cells (Itokazu et al., 2014). Hicks et al. 
(2013) have demonstrated that CTX0E03 
cells express both trophic and pro-
angiogenic factors (VEGF, EGF, bFGF, 
ANGPT1, TGFβ1, HIF-1α and ANGPT2).  
In AD, tau is abnormally hyper-phos-
phorylated and forms into paired helical fil-
aments in neurons (Iqbal et al., 2010). Acti-
vation of protein kinase and/or inhibition of 
protein phosphatases are the likely cause(s) 
of tau hyper-phosphorylation (Wang et al., 
2014). OA, a phosphatase 2A inhibitor, has 
been used widely to induce hyper-phosphor-
ylation of tau in order to stimulate neural 
death in culture and enhance Aβ deposition, 
synaptic loss, as well as memory impairment 
in AD animal models (Barrio et al., 2011; Li 
et al., 2011; Kamat et al., 2013). CTX0E03 
cells were exquisitely susceptible to OA cy-
totoxicity. DMSO as vehicle does not affect 
CTX and NS cell viability compared to cul-
ture media or PBS (data not shown) (Kong et 
al., 2015). OA treatment in primary rat corti-
cal neurons resulted in an increased number 
of mature lysosomes and induced neuronal 
cell death (Cho et al., 2013). High concentra-
tions of OA decrease axonal outgrowth and 
branching, as well as inducing depression of 
growth-associated protein-43 (an axonal 
growth regulator) (Das and Miller, 2012).  
In conclusion, our study indicates the 
ability of clinical grade CTX0E03 stem cell 
line to resist the inhospitable milieu associat-
ed with AD. Thus, CTX0E03 stem cells pro-
vide a potential candidate for cell therapy in 
AD patients. 
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